Form 4: Quince Therapeutics Executive Reports Option Exchange

Chief Corporate Affairs Officer Brigette Roberts reports the exchange of Orphai Therapeutics stock options for Quince Therapeutics options following a merger.

Summary

• Brigette Roberts, Chief Corporate Affairs Officer at Quince Therapeutics, Inc., received new stock options in the company as part of a merger agreement with Orphai Therapeutics, LLC.
• The transaction involved the exchange of various tranches of Orphai stock options for Quince Therapeutics options.
• The new options have exercise prices of $0.09 and $0.84 per share.
• Most of the acquired options are immediately exercisable, with one specific tranche of 6,837,319 shares vesting in 36 equal monthly installments beginning May 21, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing documenting the expected equity adjustments following a previously announced merger.

Positives

• Alignment of executive interests with the combined entity post-merger.
• Retention of key leadership talent through the transition period.

Negatives

• Dilutive potential from the issuance of a significant number of new stock options.

Risks

• Integration risks associated with the merger of Orphai Therapeutics into Quince Therapeutics.
• Market volatility affecting the value of the newly issued options.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing instead on the equity compensation structure resulting from the merger.

Management Comments

• The transactions were executed pursuant to the Agreement and Plan of Merger dated May 17, 2026.

Industry Context

StockSavvy.ai notes that this filing reflects standard post-merger equity conversion practices in the biotechnology sector, where legacy options are typically rolled into the acquiring company's equity plan to maintain executive retention.

Comparison to Industry Standards

• The exchange of options at a set ratio is consistent with standard M&A practices in the life sciences industry.
• The use of a 36-month vesting schedule for a portion of the options is aligned with typical executive retention benchmarks.

Related Party Transactions

• The transaction is a result of the merger between Quince Therapeutics and Orphai Therapeutics, involving the exchange of equity interests.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new options.
• Employees and executives of the acquired entity are integrated into the Quince Therapeutics compensation structure.

Next Steps

• Vesting of the 6,837,319 options in 36 monthly installments starting May 21, 2026.

Key Dates

Keywords

Quince Therapeutics, QNCX, Form 4, Stock Options, Merger, Insider Trading, Orphai Therapeutics